In this issue of Clinical Watch, we provide updates on COVID-19 and highlight several high-cost therapies that could be approved and on the market by end of 2021. Lastly, we review claims data for ibuprofen following the suggestion early on in the pandemic that it might worsen the severity of COVID-19 infection.
For more information about a topic, please contact Janelle Sheen, Karen Powell or Mary-Beth Plum. Be sure to watch for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.